Surface modification via strain-promoted click reaction facilitates targeted lentiviral transduction  by Chu, Yanjie et al.







Universjournal homepage: www.elsevier.com/locate/yviroBrief CommunicationSurface modiﬁcation via strain-promoted click reaction facilitates
targeted lentiviral transduction
Yanjie Chu a, Yoon Hyeun Ouma,1, Isaac S. Carrico a,b,n
a Department of Chemistry, State University of New York at Stony Brook, Stony Brook, NY 11794-3400, USA
b Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY 11794-3400, USAa r t i c l e i n f o
Article history:
Received 28 May 2015
Returned to author for revisions
19 September 2015
Accepted 21 September 2015












22/& 2015 Elsevier Inc. All rights reserved.
esponding author at: Department of Chemis
Stony Brook, Stony Brook, NY 11794-3400,
631 632 7960.
ail address: isaac.carrico@stonybrook.edu (I.S.
esent address: Department of Radiology an
ity, Atlanta, GA 30322, USA.a b s t r a c t
As a result of their ability to integrate into the genome of both dividing and non-dividing cells, lenti-
viruses have emerged as a promising vector for gene delivery. Targeted gene transduction of speciﬁc cells
and tissues by lentiviral vectors has been a major goal, which has proven difﬁcult to achieve. We report a
novel targeting protocol that relies on the chemoselective attachment of cancer speciﬁc ligands to
unnatural glycans on lentiviral surfaces. This strategy exhibits minimal perturbation on virus physiology
and demonstrates remarkable ﬂexibility. It allows for targeting but can be more broadly useful with
applications such as vector puriﬁcation and immunomodulation.
& 2015 Elsevier Inc. All rights reserved.Introduction
Over the past two decades, lentiviral vectors have been used
widely as a gene delivery system for both therapeutic and basic bio-
logical applications (Dropulic, 2011; Emeagi et al., 2013; Sakuma et al.,
2012), largely due to their ability to mediate stable, long term trans-
gene expression by integrating into the genome of both dividing and
non-dividing cells. Compared to their counterpart γ-retroviruses,
lentiviruses are less prone to insertional mutagenesis (Montini et al.,
2009,2006), capable of accommodating larger genes (De Meyer et al.,
2006), and have the unique advantage of transducing target cells
without complete cell division (Naldini, 1998; Naldini et al., 1996), a
feature especially suited for resting and differentiated cells such as
hematopoietic stem cells (Wagemaker, 2014), macrophages (Leyva
et al., 2011) and neurons (Hutson et al., 2014). With demonstrable
clinical safety (Liechtenstein et al., 2013), these vectors present an
attractive alternative therapy for a variety of genetic diseases (Cartier
et al., 2009; Cavazzana-Calvo et al., 2010), cancer (Kalos et al., 2011) astry, State University of New
USA. Tel.: þ1 631 632 7935;
Carrico).
d Imaging Sciences, Emorywell as infectious diseases (Coutant et al., 2012; Tebas et al., 2013). In
addition to the introduction of complementary therapeutic genes into
target cells, lentiviral victors have been developed to induce gene
silencing by siRNAs (Hutson et al., 2014; Manjunath et al., 2009;
Sumimoto and Kawakami, 2007), and deliver genetic material to
antigen-presenting cells for vaccination (Hu et al., 2011). In the context
of laboratory and preclinical applications, lentiviral vectors have been
widely used in functional genetics, cell engineering and generating
animal model systems (Dropulic, 2011; Sakuma et al., 2012).
Extensive effort has been invested in the modiﬁcation of the
envelope glycoprotein of lentivirus to generate vectors with
enhanced properties such as restricted cell tropism (Anliker et al.,
2010; Lei et al., 2010; Liang et al., 2013; Morizono et al., 2009a,
2009b, 2005), easier puriﬁcation (Yu and Schaffer, 2006) and
reduced immunogenicity (Croyle et al., 2004; Hwang and Schaffer,
2013). Surface glycoproteins of lentivirus can be substituted by
those of another virus, commonly termed pseudotyping, which is
often used to alter the cell speciﬁcity of the vector or to improve
particle stability and production (Cronin et al., 2005). Other meth-
ods for surface engineering of lentiviral vectors include genetic
manipulation of the envelope protein sequence (Funke et al., 2008;
Höﬁg et al., 2014; Morizono et al., 2001, 2009a, 2009b, 2005;
Munch et al., 2011; Yu and Schaffer, 2006), non-covalent mod-
iﬁcation with bridging moieties such as antibodies (Morizono
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enveloping of virus vectors with a fusogenic protein and a
membrane-bound targeting protein (Eleftheriadou et al., 2014; Lee
et al., 2011; Lei et al., 2009, 2010; Yang et al., 2006), and chemical
modiﬁcation through the primary amino groups on surface exposed
lysine residues (Croyle et al., 2004; Liang et al., 2013). Low virus titer
and transductional efﬁciency can result from genetic modiﬁcation
of the lentiviral envelope, and the type of motifs that can be
introduced is limited. The targeting molecules in co-enveloping
strategies are limited to membrane-bound proteins (Eleftheriadou
et al., 2014; Lee et al., 2011; Lei et al., 2009, 2010; Yang et al., 2006).
Although the bridging adaptor approach demonstrates wide sub-
strate scope, it requires multistep procedures and the in vivo sta-
bility of these complexes is debatable. Lysine acylation also allows
access to a wide variety of effector moieties, however, efﬁciency is
relatively low, speciﬁcity is problematic and the chemistry will be
adversely affected by the presence of other nucleophiles in the
sample. As a result, additional methods of surface functionalization
that are ﬂexible, efﬁcient, broadly applicable, and highly speciﬁc
could aid in the development of next generation lentiviral vectors.
Unlike more conventional in vitro bioconjugation methods, such as
electrophilic modiﬁcation of free lysines and cysteines, azide–alkyne
cycloaddition (Agard et al., 2004; Baskin et al., 2007; Rostovtsev et al.,
2002; Sletten and Bertozzi, 2008; Tornøe et al., 2002) and Staudinger
ligation (Saxon and Bertozzi, 2000) reactions are highly selective, well-
controlled and fast, making them preferable in complex biological
systems. Metabolic incorporation of unnatural substrates bearing azide
or terminal alkyne functionalities has been utilized to label glycans
(Chang et al., 2009; Laughlin and Bertozzi, 2007), lipids (Kho et al.,
2004), DNA (Neef and Luedtke, 2011) and proteins (Dieterich et al.,
2006). Bertozzi and coworkers have demonstrated the metabolic
incorporation of an azido sialic acid analog, N-azidoacetyl sialic acid
(SiaNAz), onto cell surface glycoproteins as a chemical reporter for
both in vitro and in vivo studies (Agard et al., 2004; Luchansky et al.,
2003; Prescher et al., 2004; Saxon and Bertozzi, 2000). As the envel-
opes of lentiviruses are derived from portions of the host cellFig. 1. Two step labeling method for surface modiﬁcation of lentiviral vectors. (A) Prod
onto viral surface glycans. Further modiﬁcation via SPAAC facilitates installation of variou
FLAG tag western blot conﬁrmed the incorporation of SiaNAz onto the surface of VSV-
SiaNAz residues on the viral surface. Prior to SPAAC modiﬁcation, each virus sample was
neuraminidase (2.5 U/mL) or merely the buffer at 37 °C for 1 h. Each reaction sample wa
with BCN-PEG-FLAG (300 μM) or only the buffer at room temperature for 6 h. The re
acrylamide gels followed by western blotting with an anti-FLAG antibody. The moleculamembranes, with the viral glycoproteins generated by the cellular
biosynthetic machinery, we hypothesized that sialylated viral glyco-
proteins could be labeled through the same strategy used to label
cellular proteins (Fig. 1A). As chemical “handles”, the introduced azide
groups are small, inert and expected to have little impact on virus
assembly and function. Several azide-speciﬁc chemical reactions can
be employed for subsequent modiﬁcation of the viral surface,
including the Staudinger ligation, Cu(I)-catalyzed azide–alkyne
cycloaddition (CuAAC), and strain-promoted azide–alkyne cycloaddi-
tion (SPAAC), giving access to virtually any functionality desired. In this
work the novel SPAAC reagent bicyclo[6.1.0]nonyne (BCN) featuring
the combination of easy preparation, high reactivity and relatively low
lipophilicity was used (Dommerholt et al., 2010) (Fig. 1A). We report
here viral surface conjugation with 3 targeting ligands. One is small
molecule ligand selective for prostate-speciﬁc membrane antigen
(PSMA) and the other two are peptides that are known to localize in
angiogenic regions. Simple and efﬁcient SPAAC modiﬁcation of viral
surfaces signiﬁcantly enhanced transduction toward cells bearing the
targeted cell surface receptors.Results
Metabolic incorporation of SiaNAz onto lentiviral surface
Vesicular stomatitis virus glycoprotein (VSV-G) is the most
commonly used glycoprotein for pseudotyping lentiviruses due to
its broad tropism, and ability to enable high-titer vector prepara-
tion (Cronin et al., 2005). As a result, VSV-G pseudotyped lenti-
viruses were chosen as a platform to test SiaNAz mediated surface
labeling. Each pseudotyped lentivirus particle is encapsulated with
approximately 216 copies of VSV-G (Croyle et al., 2004), containing
two complex N-linked oligosaccharides at amino acids 179 and
336 (Puri et al., 1992). Both the extent of sialylation of the oligo-
saccharides and the ability of SiaNAz to replace sialic acid depend
on the cell line in which the virus proteins are produced (Etchisonuction of lentivirus in the presence of Ac4ManNAz leads to incorporation of SiaNAz
s functional molecules. (B) Structure of the reporter ligand BCN-PEG-FLAG. (C) Anti-
G enveloped lentivirus. The BCN-PEG-FLAG ligand was used to selectively modify
suspended in a reaction buffer (50 mM sodium citrate, pH 6.0) and incubated with
s then run through a size-exclusion spin column equilibrated in PBS, and incubated
action samples were subsequently analyzed by electrophoresis on 10% SDS-poly-
r weight of VSV-G is 67 kDa (Cannon et al., 1996).
Fig. 2. Impact of the metabolically introduced azides on virus production and
transduction efﬁciency. Production of virus particles with or without addition of
Ac4ManNAz was examined by p24 ELISA assays on the (A) unconcentrated virus-
containing supernantant and (B) virus samples concentrated by ultracentrifugation.
Each virus sample was assayed in triplicate and average value was reported. Error
bars indicate standard deviation. Transduction titers of the virus samples were
examined by infecting HEK293T cells and detecting transgene (GFP) expression by
ﬂow cytometry. Titers of the (C) unconcentrated and (D) concentrated virus sam-
ples were calculated based on percentage of GFP positive cells. 2.5 mL, 5 mL and
10 mL aliquots of each unconcentrated virus sample and 100 fold diluted con-
centrated virus sample was used in transduction, each amount was assayed in
triplicate. Average value of all the calculated TU titers of each virus sample was
reported. Error bars indicate standard deviation. Transduction efﬁciency values
(TU/ng p24) of (E) unconcentrated and (F) concentrated virus samples were cal-
culated by dividing the transduction titer values in (C) and (D) by the average p24
concentrations in (A) and (B) respectively.
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shown to be directly incorporated into surface sialoglycoconju-
gates by mammalian cells (Oetke et al., 2002, 2001). Yet, the more
synthetically accessible precursor peracetylated N-α-azidoace-
tylmannosamine (Ac4ManNAz) (Fig. 1A) has demonstrated similar
metabolic efﬁciency as the corresponding sialic acid analog has
(Luchansky et al., 2004b), and was therefore preferred in this
work. When grown in medium with an initial Ac4ManNAz con-
centration of 50 mM, the lentivirus producing cell HEK293T
exhibited about 27% substitution of cell surface sialic acid by Sia-
NAz (Chang et al., 2009). However, it is unknown whether the
incorporation plateaus at this concentration. In addition, the
labeling efﬁciency of a single glycoprotein species, VSV-G in the
case of this work, may vary from the average of the whole glyco-
protein population of the cell.
Lentiviral vectors were produced using the calcium phosphate
transfection method (Kutner et al., 2009). In a reported test of
calcium phosphate transfection on HEK293 cells, it has been
shown that plasmid expression, when tested 48 h after transfec-
tion, reached a plateau after 5–7 h of coincubation with the DNA/
Ca-Pi coprecipitates (Batard et al., 2001). Although the required
coincubation time may vary for a different cell line, we used this
data as a guideline and applied Ac4ManNAz 7 h after beginning of
transfection, avoiding possible complications the unnatural sub-
strate and ethanol (solvent of the stock solution) may impose on
plasmid uptake. Transfection medium was then replaced with
fresh medium also containing 75 mM of Ac4ManNAz 16–18 h after
beginning of transfection. Virus containing supernatant was col-
lected and concentrated 48 h after transfection.
Strain promoted “click” chemistry (SPAAC) has the advantage of
being fast, highly selective for azides, and does not require the
addition of a toxic catalyst. In order to access this chemistry,
labeling/targeting moieties were modiﬁed with a previously
described strained alkyne, bicyclo[6.1.0]nonyne (BCN) (Fig. 1A). To
demonstrate SiaNAz incorporation, viruses produced in the pre-
sence of Ac4ManNAz were exposed to a BCN armed FLAG epitope
(300 mM BCN-FLAG; 6 h at room temperature) and analyzed by
anti-FLAG western blot (Fig. 1B and C). The result indicated suc-
cessful installation of SiaNAz onto the surface of VSV-G pseudo-
typed lentivirus. Notably there is a complete loss in signal with
omission of either the azido sugar or BCN-FLAG. Neuraminidase
treatment prior to SPAAC reaction also completely abrogates sig-
nal, indicating the azide speciﬁc labeling is directly associated with
sialic acid residues (Fig. 1C).
Impact of SiaNAz incorporation on virus production and infectivity
In contrast to genetic manipulations of envelope proteins,
introduction of SiaNAz is post-translational and results in the
addition of only 3 atoms per site of incorporation. As a result,
SiaNAz introduction is expected to cause minimal impact on the
physiology of labeled lentiviral vectors. The impact of SiaNAz
incorporation on both viral particle production and infectivity was
determined. The former was assayed via p24 titer, whereas the
latter was measured by quantifying gene delivery to cells via ﬂow
cytometry. With the addition of Ac4ManNAz during virus pro-
duction, p24 ELISA demonstrated a reduction of titer (ng p24/mL)
by 26% for unconcentrated samples and 22% for samples con-
centrated by ultracentrifugation (Fig. 2A and B). Transduction
assays examining expression of the GFP transgene in HEK293T
cells exhibited a reduction of functional titer (TU/mL) by 11% for
unconcentrated samples and 7% for concentrated (Fig. 2C and D).
Surprisingly, transduction efﬁciency values (TU/ng p24) calculated
from these two types of titers showed an increase of infectivity by
20% for unconcentrated samples and 19% for concentrated (Fig. 2E
and F).These results indicate that neither the production of viral par-
ticles nor the gene delivery function of labeled lentiviral vectors is
signiﬁcantly affected by the metabolically incorporated SiaNAz. It
is also evident that physical stress from ultracentrifugation did not
result in larger difference in functional titers between azide (þ)
and azide () samples, suggesting that the stability of labeled
lentiviral particles was not compromised by the metabolic incor-
poration of SiaNAz (Fig. 2C and D).
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Transductional targeting of lentiviral vectors towards speciﬁc
cells or tissues is an attractive goal, particularly for in vivo appli-
cations. Towards this goal, we designed several targeting ligands
equipped with BCN for SPAAC modiﬁcation of viral surfaces. In
order to restrict endogenous cell tropism, we used lentiviruses
pseudotyped with a mutant Sindbis glycoprotein. Chen and cow-
orkers introduced a series of mutations into the Sindbis virus
envelope proteins that resulted in reduced binding to the natural
cell surface receptors, heparan sulfate and laminin receptor, while
maintaining relatively high lentiviral vector production (Morizono
et al., 2005). One of these detargeted mutants containing a 14 aa
ﬂexible linker inserted at the original receptor binding region and
termed as “2.2 1L1L” (Morizono et al., 2009a) was used in
this work.
Sindbis virus envelope proteins, composed of two 50 kDa
transmembrane glycoproteins E1 and E2 (von Bonsdorff and Har-
rison, 1975), contain two complex N-glycans at amino acid 196 on
E2 and aa 139 on E1, both exposed (Morizono et al., 2010). Akin to
VSV-G pseudotyped vectors, the extent of sialylation of Sindbis
glycoproteins depends on the cell lines in which they are produced
(Burke and Keegstra, 1979). Importantly, these sites of glycosyla-
tion are unperturbed by the detargeting mutations described by
Chen and coworkers (Morizono et al., 2010). 2.2 1L1L Sindbis
envelope protein pseudotyped lentiviral vectors were produced by
the same procedures used for VSV-G pseudotyped vectors, differ-
ing only in the envelope encoding plasmid used in transfection.
Incorporation of SiaNAz onto the viral surface was conﬁrmed by
reaction with 300 mM BCN-FLAG and following western blot
(Fig. 3A), and the impact on viral particle production was eval-
uated by a p24 ELISA assay. With the addition of Ac4ManNAz
during virus production, a reduction of titer (ng p24/mL) by 18%
was observed for samples concentrated by ultracentrifugation
(Supplementary Fig. S1).
Lentiviral vectors have long been explored for cancer gene
therapy, where they have been used to deliver cytotoxic genes
(Diaz et al., 2000; Huszthy et al., 2009; Ravet et al., 2010), RNAi
(Sumimoto and Kawakami, 2007), or antigenic genes designed for
cancer immunotherapy (Breckpot et al., 2007; Hu et al., 2011). The
therapeutic potential of lentiviral vectors can be greatly improved
through targeting of the vectors to tumor cells, facilitating direct
in vivo application. Three high-proﬁle cancer associated receptors
were targeted in the context of this approach, vascular endothelial
growth factor receptor 2 (VEGFR2), αvβ3 integrin and PSMA.
Ligands for these receptors have been extensively developed and,
as a result, have facile modiﬁcation routes for installation of SPAAC
capable cyclooctyne motifs.
As an angiogenic factor, vascular endothelial growth factor
(VEGF) plays a crucial role in facilitating tumor vascularization and
presents an important target for anticancer therapy (Kowanetz
and Ferrara, 2006). Through phage display Mazié and colleagues
identiﬁed an effective peptide antagonist of VEGF, ATWLPPR
(Binetruy-Tournaire et al., 2000). A nitrophenyl carbonate of BCN
was synthesized as described by van Delft and coworkers (Dom-
merholt et al., 2010), and used in the coupling reaction with the
amine terminus of this peptide antagonist, which contains two
extra glycine residues as a short spacer (Supplementary Scheme
S2). The resulting VEGFR2 targeting ligand BCN-GGATWLPPR
(Fig. 3B) was used in surface modiﬁcation of lentiviral vectors
and tested for elevated transduction on a VEGFR2 over-expressing
cell line HUVEC (Fig. 3C).
Cell adhesion αvβ3 integrin, over-expressed in blood vessels of
tumors, is required in tumor-induced angiogenesis and tumor
metastasis. We developed a bicyclononyne functionalized integrinαvβ3 targeting ligand based on a highly potent and selective
antagonist ﬁrst designed and synthesized by Kessler's group, the
cyclic pentapeptide c(RGDfK) (Haubner et al., 1996). Compared to
the RGD-4C version of cyclic RGD, where the RGD motif is cyclized
through disulﬁde bonds, the cyclic(RGDfK) peptide, which con-
tains a D-phenylalanine and is cyclized via an amide bond, has
higher afﬁnity and speciﬁcity toward integrin αvβ3. The cyclic
peptide was synthesized using Fmoc solid-phase chemistry
according to the scheme described by the Liu group (Dai et al.,
2000). The nitrophenyl carbonate of BCN was again used in the
coupling reaction with the primary amino group on the lysine
residue contained in the cyclic(RGDfK) (Supplementary Scheme
S3). The resulting ligand BCN-c(RGDfK) (Fig. 3B) was used in sur-
face modiﬁcation of letiviral vectors. The transduction efﬁciency of
the modiﬁed vectors was then tested on an integrin αvβ3 over-
expressing cell line U-87 MG (Fig. 3D).
PSMA is a type II transmembrane protein expressed in all types
of prostate tissues and at increased levels in prostate cancer tis-
sues (Kawakami and Nakayama, 1997; Wright et al., 1995). Addi-
tionally, it is robustly expressed in the neovasculature of various
nonprostatic solid malignancies (Chang et al., 1999; Silver et al.,
1997). Kozikowski and coworkers synthesized and tested a series
of glutamate urea derivatives designed to inhibit PSMA. An analog
bearing a γ-tetrazole on one of the glutamic acid moieties was
identiﬁed as the most potent inhibitor with a Ki of 0.9 nM (Kozi-
kowski et al., 2004). Spiegel and coworkers adopted this design
and proposed a 1-butyl-4-alkyl-1,2,3-triazole analog for the con-
struction of the cell-binding terminus in their antibody recruiting
small molecule (Murelli et al., 2009). This scaffold was synthesized
using a similar route to that described by Spiegel and colleagues,
with a slightly different linker region, and conjugated to BCN via
the same coupling scheme used for the two peptide ligands
(Supplementary Scheme S4). The resulting PSMA targeting ligand
BCN-PEG-glutamate urea (Fig. 3B) was tested on a human prostate
cancer cell line LNCaP (Fig. 3E).
In each targeting assay, lentiviral vectors metabolically labeled
with SiaNAz were incubated with a BCN functionalized ligand
(600 mM) for 6 h at room temperature and used in transduction of
target cells immediately after removal of excess ligand by size
exclusion spin columns. Expression of the GFP transgene was
analyzed by ﬂow cytometry two to three days later depending on
the growth rate of the cell line tested. As controls, virus samples
produced in the absence of Ac4ManNAz or not exposed to any
BCN-ligand were tested under identical conditions. Viral surface
conjugation with the BCN-ligands effectively enhanced the trans-
duction efﬁciency toward target cells without extensive optimi-
zation of reaction conditions. Labeled vectors exhibited 3–18 fold
increased levels of transgene expression, which was speciﬁc to
both azide labeling and SPAAC modiﬁcation. It is noteworthy that
metabolic incorporation of SiaNAz alone exhibited no apparent
impact on the vectors' nonspeciﬁc transduction efﬁciency toward
the target cell lines, revealed by comparison between column
3 and 5 in each assay. Incubation of the target cells with free
ligands as inhibitors one hour prior to infection attenuated ligand
enhanced gene delivery. Notably, saturation of the cell surface
receptor with free ligand prior to exposure to viruses only partially
reduced ligand enhanced gene delivery. Presumably this is a result
of the high local concentration of targeting ligands on the virus/
cell interface associated with multidentate binding.Discussion
We have developed a simple, versatile two step labeling
method for lentiviral surface modiﬁcation. As demonstration,
three bicyclononyne equipped targeting ligands were successfully
Fig. 3. Chemoselective modiﬁcation of lentiviral vectors with BCN equipped ligands led to retargeted transduction. (A) Anti-FLAG tag western blot conﬁrmed the incor-
poration of SiaNAz onto the surface of lentivirus enveloped with a Sindbis glycoprotein mutant 2.2 1L1L. The molecular weight of both Sindbis glycoprotein E1 and E2 are
50 kDa (von Bonsdorff and Harrison, 1975). (B) Scheme showing chemoselective modiﬁcation of metabolically labeled virus though SPAAC reactions with bicyclononyne
equipped targeting ligands. (C) Modiﬁcation of the lentiviral vectors with peptide GGATWLPPR led to enhanced transduction of a VEGFR2 over-expressing cell line HUVEC.
(D) Modiﬁcation of the lentiviral vectors with cyclic RGD led to enhanced transduction of an integrin αvβ3 over-expressing cell line U-87 MG. (E) Modiﬁcation of the lentiviral
vectors with a glutamate urea derived ligand led to enhanced transduction of a prostate cancer cell line LNCaP. Each illustrated virus sample was used in the transduction of
three wells of coressponding target cells grown in 6-well plates. Expression of the GFP transgene in transduced cells was analyzed by ﬂow cytometry and the average value of
the resulting percentages of GFP positive cells was reported. Error bars indicate standard deviation.
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of targeted cells.
One advantage of our proposed technique is the minimal
impact on viral ﬁtness. Production of concentrated functional
lentiviral vectors was affected by less than 10% with the addition of
unnatural substrate (Fig. 2D). This reduction is more likely to be a
result of hindered viral production rather than compromised
infectivity of SiaNAz labeled virus. This assumption is supported by
the fact that transduction efﬁciency (TU/ng p24) was not under-
mined by the inclusion of Ac4ManNAz during viral production
(Fig. 2E and F). Possible reasons for the negative impact on viral
production include a cytotoxic effect of the unnatural substrate on
virus producing cells and impeded viral particle assembly. Whe-
ther the metabolism of Ac4ManNAz saturates at the concentration
that we used in the virus producing HEK293T cells is not yet
known, nor the potential toxicity. Incorporation percentage of
SiaNAz in total virus samples can be obtained using protocols
previously reported for cell lysate and recombinant glycoproteins,
where sialic acids and analogs were derivatized with 1,2-diamino-
4,5-methylenedioxy-benzene (DMB) and analyzed by HPLC with
ﬂuorescence detection (Luchansky et al., 2004a). However, data
from this assay may not fairly represent the sialic acid composition
on intact lentiviral particles, mainly due to the inherentcontamination by cellular components and free viral proteins from
the virus production.
Another merit of this method is that it can serve as a general,
ﬂexible route to covalently introduce synthetic molecules. Bioor-
thogonal chemical modiﬁcations on the viral surface azide groups
give access to virtually any kind of functionality, with excellent
efﬁciency and speciﬁcity. Two out of the three targeting ligands we
have conjugated to the viral surface through SPAAC, the c(RGDfK)
peptide and the glutamate urea derivative, cannot be directly
introduced by genetic insertion. Notably, excellent targeting was
seen without any optimization in ligand concentration or reaction
time. It may be advantageous to limit the number of ligands
appended to viral surface, which can alter surface charge and
aggregation propensity. Control over ligand density can easily be
obtained by altering the level of SiaNAz incorporation, through
changing the concentration of precursor azido sugar, or the efﬁ-
ciency of subsequent “click” modiﬁcation, via change in mod-
iﬁcation time or ligand concentration.
The modiﬁed Sindbis virus envelope proteins we used as the
pseudotype for the targeting assays include two glycoproteins, E1
and E2. E2 mediates binding to cellular receptors (Byrnes and
Grifﬁn, 1998; Klimstra et al., 1999; Myles et al., 2003; Wang et al.,
1992), while E1 is responsible for the fusion between the viral
envelope and the cell membrane (Sanz et al., 2003). It is plausible
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with its fusion function, especially in cases when the ligands are
bulky. However, we do expect the ligand on E1 to contribute to the
speciﬁc binding and increased transduction toward targeted cells.
It has been shown that, when expressed in a high mannose
structure, the glycan on E1 aa 139 alone can mediate higher
transduction by binding to DC-SIGN, a cell surface lectin expressed
on dendritic cells, just like the glycan on E2 aa 196 (Morizono et
al., 2010). It might be interesting to introduce mutations at E2 aa
196 or E1 aa 139 to remove the glycan and observe the effect on
our targeting system with different targeting ligands. In addition
to viral envelope proteins, some cellular proteins can also be
incorporated onto lentiviral surface during budding. While wes-
tern analysis indicates that any content of sialylated cellular pro-
tein is low, these glycoproteins may be labeled with targeting
ligand and, as a result, have some impact on cellular targeting.
In summary, we have developed a general method for labeling
Lentiviral surfaces that is both ﬂexible and robust. This method
lends itself to being applied to a wide variety of applications
including expanded targeting, puriﬁcation via modiﬁcation with
afﬁnity tags, and ﬂuorescence/MRI/PET based particle tracking.
Modiﬁcation via azido sugar introduction can be widely applied to
budded viruses. Lentiviral vectors were chosen for expediency, but
in principle this method will be accessible with any virus bearing
sialylated glycoproteins. Although most glycosylated viruses bear
sialic acid residues, alternate methods for azide introduction
include the use of other azido sugar precursors, azido amino acids
and azido lipids.Materials and methods
Synthesis
Ac4ManNAz
Peracetylated N-α-azidoacetylmannosamine (Ac4ManNAz) was
synthesized as previously described (Luchansky et al., 2003).
BCN-PEG-FLAG peptide
FLAG-Cys peptide (DYKDDDDKC) was synthesized on a
0.25 mmol scale using a CEM Liberty microwave peptide synthe-
sizer (Model no. 908505) utilizing Fmoc chemistry. Solvents used
were ACS-grade. Fmoc-Cys(Trt)-Wang resin (500 mg, 100–200
mesh, novabiochem) was used as the starting reagent for the solid
phase synthesis. Standard Fmoc reaction cycles were used. In each
cycle, 5 equiv. (1.25 mmol) of an Fmoc amino acid (Fmoc-Asp
(OtBu)-OH, Fmoc-Lys(Boc)-OH or Fmoc-Tyr(tBu)-OH) was acti-
vated by DIPEA and HBTU and attached to the growing peptide in a
single coupling step (300 s, 75 °C), followed by removal of the
Fmoc group in two deprotection steps (30 s and 180 s, 75 °C) by
20% piperidine in DMF with HOBt. Resin was washed with DCM
and collected by vacuum ﬁltration before cleavage of the peptide
using a mixture (10 mL) of 90% TFA, 5% thioanisole, 3% EDT and 2%
anisole for 2 h. Resin was then removed by vacuum ﬁltration
through a sintered glass funnel, and washed twice with TFA. The
resulting solution was concentrated to 2 mL by blowing Ar on
the surface, and added drop wise into diethyl ether to precipitate
the peptide. The precipitate was re-dissolved in 10% acetic acid
(30 mL) and lyophilized to afford 310.7 mg of crude FLAG-Cys
peptide. 87.4 mg crude peptide was then puriﬁed by reversed-
phase HPLC using a Phenomenex Jupiter C12 semi-preparative
column (25010 mm, Part no. 00G-4396-N0), eluting with a
gradient of acetonitrile in water (5–25% over 40 min, ﬂow rate
4 mL/min). TFA (0.1%) was included in the mobile phase as the ion-
pairing reagent. Subsequent lyophilization afforded puriﬁed FLAG-Cys peptide (21.3 mg, 27%). MS (MALDIþ): m/z calcd for
[C44H66N11O21S]þ [M þ H]þ: 1116.415, found: 1117.229.
(1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethyl 3,6,9-trioxa-12-
azadodecylcarbamate (endo-1) was synthesized as previously
described (Dommerholt et al., 2010). To a solution of endo-1
(10.3 mg, 31.7 μmol) in anhydrous acetonitrile (400 μL) was added
triethylamine (4 μL) and NHS-PEG8-maleimide (20 mg, 29.0 μmol,
Thermo Scientiﬁc). The reaction was then allowed to proceed at
room temperature for 12 h with rotation (Supplementary Scheme
S1). The resulting BCN-PEG-maleimide was puriﬁed by reversed-
phase HPLC using a Phenomenex Jupiter C12 semi-preparative
column (25010 mm, Part no. 00G-4396-N0), eluting with a
gradient of acetonitrile in water (10–50% over 40 min, ﬂow rate
4 mL/min). TFA (0.1%) was included in the mobile phase as the ion-
pairing reagent. Subsequent removal of solvent by lyophilization
afforded puriﬁed BCN-PEG-maleimide (15 mg, 58%). MS (ESIþ):
m/z calcd for [C43H71N4O16]þ [M þ H]þ: 899.486, found: 899.35.
Puriﬁed FLAG-Cys peptide (8.0 mg, 7.2 mmol) was dissolved in
reducing buffer (500 μL, 20 mM EDTA, 10 mM TCEP, 50 mM
sodium phosphate pH 7.0) and rotated on a Labquake Shaker
Rotisserie (Thermo Scientiﬁc) at room temperature for 1 h. To a
suspension of BCN-PEG-maleimide (6.4 mg, 7.1 mmol) in 500 μL of
CH3CN/H2O (4:1) was added the FLAG-Cys containing solution.
After the reaction mixture was rotated at room temperature for
2 h, DMSO (200 mL) and an additional aliquot of BCN-PEG-
maleimide (2.2 mg, 2.4 mmol) was added. The reaction mixture
was then rotated for an additional 6 h (Supplementary Scheme
S1). The product BCN-PEG-FLAG was puriﬁed by reversed-phase
HPLC using a Phenomenex Jupiter C12 semi-preparative column
(25010 mm, Part no. 00G-4396-N0), eluting with a gradient of
acetonitrile in water (5% for 5 min, then 5–45% over 40 min, ﬂow
rate 4 mL/min). TFA (0.1%) was included in the mobile phase as the
ion-pairing reagent. Subsequent removal of solvent by lyophiliza-
tion afforded puriﬁed BCN-PEG-FLAG (3.5 mg, 1.7 mmol, 24%). MS




carbonate (endo-2) was synthesized as previously described
(Dommerholt et al., 2010). The same protocol used in the synthesis
of the FLAG-Cys peptide was followed to synthesize the VEGFR2
targeting peptide GGATWLPPR using a CEM Liberty microwave
peptide synthesizer (Model no. 908505). To a solution of peptide
GGATWLPPR (3.3 mg, 3.5 μmol) in DMSO (400 μL) was added
triethylamine (9 μL) and endo-2 (3.3 mg, 10.4 μmol). The reaction
was then rotated at room temperature for 6 h (Supplementary
Scheme S2). The resulting BCN-GGATWLPPR was puriﬁed by
reversed-phase HPLC using a Varian C18 analytical column
(2504.6 mm, Part no. R0086200C5), eluting with a gradient of
acetonitrile in water (5% for 5 min, then 5–50% over 55 min, ﬂow
rate 1 mL/min). TFA (0.1%) was included in the mobile phase as the
ion-pairing reagent. Subsequent removal of solvent by vacuum
afforded puriﬁed BCN-GGATWLPPR (1.2 mg, 30%). MS (MALDIþ):




carbonate (exo-2) was synthesized as previously described
(Dommerholt et al., 2010). Cyclo(-Arg-Gly-Asp-D-Phe-Lys-) was
synthesized manually based on published procedures (Dai et al.,
2000). To a solution of c(RGDfK) (5.0 mg, 6.0 μmol) in DMF
(500 μL) was added triethylamine (10 μL) and exo-2 (7.3 mg,
20 μmol). The reaction was rotated at room temperature for 8 h
(Supplementary Scheme S3). The resulting BCN-c(RGDfK) was
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column (2504.6 mm, Part no. R0086200C5), eluting with a
gradient of acetonitrile in water (15–50% over 35 min, ﬂow rate
1 mL/min). TFA (0.1%) was included in the mobile phase as the ion-
pairing reagent. Subsequent removal of solvent by vacuum affor-
ded puriﬁed BCN-c(RGDfK) (1.9 mg, 40%). MS (ESIþ): m/z calcd for
[C38H54N9O9]þ [M þ H]þ: 780.404, found: 780.3.
BCN-PEG-glutamate urea
To a solution of 4-pentynoic acid (196.2 mg, 2mmol) and N-
hydroxysuccinimide (230.2 mg, 2 mmol) in DCM (20 mL) at 0 °C
was added N,N0-Dicyclohexylcarbodiimide (495.2 mg, 2.4 mmol).
The resulting mixture was stirred at room temperature for 5 h. The
DCU precipitate was removed by ﬁltration, and to the ﬁltrate was
added Trt-NH-(PEG)2-NH2 (105 mg, 0.227 mmol, Novabiochem,
Cat. no. 01-63-0143). The reaction mixture was stirred for 13 h,
and ﬁltered again. The product in the ﬁltrate was puriﬁed by col-
umn chromatography on silica gel (EtOAc 100%). Rf¼0.2 (EtOAc
100%). All puriﬁed alkyne-PEG-NH-Trt was dissolved in 20 mL dry
DCM, and to the solution was added 1 mL TFA. The solution was
then stirred at room temperature for 3 h, and the crude product
was concentrated over high vacuum (Supplementary Scheme S4).
(S)-di-tertbutyl 2-(3-((S)-6-azido-1-tert-butoxy-1-oxohexan-2-
yl)ureido)pentanedioate (3) was synthesized following published
procedures (Murelli et al., 2009). A mixture of 3 (10.5 mg,
20 μmol) and alkyne-PEG-NH2 (crude, 15.8 mg) was dissolved in a
mixture of tert-butanol (500 μL) and water (130 μL) in a 1.7 mL
eppendorf tube. To this solution was added 50 mM sodium
ascorbate (200 μL, 10 μmol), 50 mM copper (II) sulfate (20 μL,
1 μmol), 10 mM TBTA (100 μL, 1 μmol) in DMSO, and 1 M Tris
buffer (pH 7.5, 50 μL, 50 μmol). The tube was then ﬂushed with Ar
and rotated at room temperature for 12 h (Supplementary Scheme
S4). The resulting compound named t-butyl-glutamte urea-NH2
was puriﬁed by reversed-phase HPLC using a Phenomenex Jupiter
C12 semi-preparative column (25010 mm, Part no. 00G-4396-
N0), eluting with a gradient of acetonitrile in water (10–70% over
60 min, ﬂow rate 4 mL/min). TFA (0.1%) was included in the mobile
phase as the ion-pairing reagent. Subsequent removal of solvent
by vacuum afforded puriﬁed t-butyl-glutamte urea-NH2 (12.7 mg,
78%). MS (ESIþ): m/z calcd for [C39H72N7O11]þ [M þ H]þ:
814.528, found: 814.5.
Puriﬁed t-butyl-glutamte urea-NH2 (5.4 mg, 6.6 μmol) was
treated by a mixture of 300 μL DCM and 700 μL TFA for 3 h to
remove the t-butyl protecting groups. Solvent was then removed
by vacuum. To a solution of the resulting crude glutamate urea-
PEG-NH2 in DMSO (400 μL) was added triethylamine (10 μL) and
endo-2 (6.3 mg, 20 μmol). Reaction was allowed to proceed at
room temperature for 3 h (Supplementary Scheme S4). The pro-
duct was puriﬁed by reversed-phase HPLC using a Varian C18
analytical column (2504.6 mm, Part no. R0086200C5), eluting
with a gradient of acetonitrile in water (5% for 5 min, then 5–50%
over 55 min, ﬂow rate 1 mL/min). TFA (0.1%) was included in the
mobile phase as the ion-pairing reagent. Subsequent removal of
solvent by vacuum afforded puriﬁed BCN-PEG-glutamate urea
(1.6 mg, 30%). MS (ESIþ):m/z calcd for [C38H60N7O13]þ [M þ H]þ:
822.425, found: 823.1.
Cells and viruses
All cell lines used in this work were grown at 37 °C in a 5% CO2
environment in a humidiﬁed incubator. HEK 293T cells (gift of Dr.
Soosan Ghazizadeh, Stony Brook University) were maintained at
low passage in Dulbecco's modiﬁed Eagle's medium (DMEM) with
10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL
streptomycin. To produce VSV-G glycoprotein pseudotyped lenti-
virus, HEK 293T cells were seeded into 10-cm tissue culture dishesat the density of 3.3106 cells per dish. Twenty four hours later,
each dish of cells was transfected with 10 μg of pMD.G (VSV-G),
20 μg of pCMVΔR8.91, and 20 μg of pHR.EF1α.GFP.WPRE.sin (all
three plasmids were gifts of Dr. Soosan Ghazizadeh, Stony Brook
University) using standard calcium phosphate transfection. For
production of SiaNAz labeled virus, Ac4ManNAz in 50 mM stock
solution was added into culture medium to the ﬁnal concentration
of 75 μM 7 h after initiation of transfection. 16–18 h after begin-
ning of transfection, medium was removed by aspiration and cells
were washed once with fresh medium before 7 mL of complete
DMEM was added per dish. Again, for the production of SiaNAz
labeled virus, 75 μM of Ac4ManNAz was included in culture
medium. Virus containing medium was collected after another
48 h and ﬁltered through 0.45 μm sterile ﬁlter (VWR, Cat. no.
28145-481) to remove cell debris. Resulting virus samples was
further concentrated by ultracentrifugation using a SW41 rotor for
2 h 20 min at 25,000 rpm (82,700 g). The virus was stored at
80 °C until use.
Sindbis virus glycoprotein pseudotyped lentivirus was pro-
duced by the same procedure, only the plasmid pMD.G (VSV-G)
was replaced with the plasmid 2.2 1L1L (mutated Sindbis virus
glycoprotein, gift of Dr. Irvin Chen, UCLA).
HUVEC cells were maintained at low passage in Endothelial Cell
Growth Complete Medium (Lonza, Cat. no. CC-3024). U-87 MG
cells were maintained at low passage in Eagle's Minimum Essen-
tial Medium (EMEM) with 10% fetal bovine serum (FBS), 100 U/mL
penicillin and 100 μg/mL streptomycin. LNCaP cells were main-
tained at low passage in RPMI-1640 Medium with 10% fetal bovine
serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin.
p24 ELISA assay
p24 value of lentiviral vectors was obtained by an ELISA assay
using the Lenti-XTM p24 Rapid Titer Kit (Clontech, Cat. no.
632200), following the instruction provided in the kit. For stan-
dard curve, a series of 2 fold dilutions of p24 protein (0 pg/mL,
12.5 pg/mL, 25 pg/mL, 50 pg/mL, 100 pg/mL and 200 pg/mL) were
made with complete DMEM. To ﬁt into the concentration range of
the standards, unconcentrated virus samples were diluted 103 fold,
and virus samples concentrated by ultracentrifugation were dilu-
ted 105 fold. Each dilution of standard was assayed in duplicate,
and each virus sample was assayed in triplicate. Assay was read on
a PerkinElmer VICTOR™ X5 Multilabel Plate Reader.
Transduction assay
Virus titer by transducing unit (TU) was obtained by a ﬂow
cytometry method detecting expression of the GFP transgene in
transduced HEK 293T cells. Brieﬂy, HEK 293T cells were seeded at
the density of 5104 cells per well in 6-well plates 24 h before
transduction, and the number of cells per well was counted again
using a hemacytometer immediately before transduction. Cells
were then transduced by adding 0 μL, 2.5 μL, 5 μL and 10 μL ali-
quots of an unconcentrated virus stock, or of a 100 fold diluted
concentrated virus stock. Each dilution was assayed in triplicate.
Cells were harvested 2 days later and analyzed by ﬂow cytometry.
Western blotting
The BCN-PEG-FLAG peptide was used to selectively modify
SiaNAz labeled lentiviruses. In each reaction, control or experi-
mental, 16 ng p24 value of virus sample was suspended in 40 μL
G1 reaction buffer (50 mM sodium citrate, pH 6.0, 10 buffer
supplied with neuraminidase) and incubated in the presence or
absence of 100 U of neuraminidase (New England BioLabs, Cat. no.
P0720) at 37 °C for 1 h. Each reaction was then run through a size-
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equilibrated in PBS. BCN-FLAG at a ﬁnal concentration of 300 μM
was added into the corresponding reactions, and the total volume
of each reaction was adjusted to 50 μL by PBS. The reaction mix-
tures were then incubated in room temperature for 6 h before they
were analyzed by electrophoresis on 10% SDS-polyacrylamide gels
followed by western blotting. Monoclonal ANTI-FLAGs M2-
Peroxidase (HRP) antibody (Sigma-Aldrich, Cat. no. A8592) was
used to detect FLAG peptide labeled proteins.
Targeting assays
90 ng p24 value of concentrated Sindbis virus glycoprotein
pseudotyped lentivirus was suspended in DMEM containing the
corresponding BCN conjugated targeting reagent at a ﬁnal con-
centration of 600 μM (stock solution: 10 mM in DMSO). The
reaction mixture therefore contained 6% DMSO originated from
the stock solutions of the ligands. In negative controls, equal
amount of DMSO instead of ligand stock was included in the
reaction. Each reaction mixture was then incubated in room
temperature for 6 h, desalted by a size-exclusion spin column
(Princeton Separations, Cat. no. CS-901) and used immediately in
transduction. 1/3 of each reaction was used for infection of cells in
one well of a 6-well plate. Cells were seeded one day prior to
transduction and counted right before infection. For VEGFR tar-
geting, 3104 HUVEC cells per well were infected with 30 ng p24
value of BCN-GGATWLPPR labeled virus or corresponding negative
controls for 2 h. As a control, 300 μM of GGATWLPPR peptide was
added into three wells of cells and incubated for 1 h at 37 °C before
infection to block cell surface receptors. For integrin αvβ3 target-
ing, 6104 U-87 MG cells per well were infected with 30 ng p24
value of BCN-c(RGDfK) labeled virus or corresponding negative
controls for 3 h. As a control, 200 μM of c(RGDfK) peptide was
added into three wells of cells and incubated for 1 h at 37 °C before
infection to block cell surface receptors. For PSMA targeting,
6104 LNCaP cells per well were infected with 30 ng p24 value of
BCN-PEG-glutamate urea labeled virus or corresponding negative
controls for 3 h. As a control, 200 μM of NH2-PEG-glutamate-urea
was added into three wells of cells and incubated for 1 h at 37 °C
before infection to block cell surface receptors.Acknowledgments
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